How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player which turns over around EUR 600 million annually – seems to have hit upon a solution: continuous adaptation. “What distinguishes Norgine is the organisation’s…
2024 marked a transformative year for Switzerland’s regulatory authority, Swissmedic. As part of its ambitious 2023–2026 strategy, the agency made significant strides towards digital transformation and improving access to innovative medicines while delivering a notable 12 percent increase in new drug approvals with 46 new active substances. Drive for Digital Transformation and Innovation 2024 was…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left by private industry and the state while elevating the concerns of the most important people within healthcare: patients and their caregivers. Rare Diseases –…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share of a global market set to top USD 93.7 billion by 2030 The field can already boast two bona-fide blockbusters: Roche’s Vabysmo (faricimab), which…
